European cancer mortality predictions for the year 2016 with focus on leukaemias

Malvezzi, Matteo; Carioli, Greta; Bertuccio, Paola; Rosso, Tiziana; Boffetta, Paolo; Levi, Fabio; Vecchia, Carlo La; Negri, Eva

doi:10.1093/annonc/mdw022

Cited by 169 publications

(125 citation statements)

References 35 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…In the United States, prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer mortalities in men (19). In Europe, approximately 75,800 patients were estimated to die from prostate cancer in 2016 (20). Its mortality ranks the third in all male malignant tumors.…”

Section: Discussionmentioning

confidence: 99%

Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis

Tao¹,

Shen²,

Xiao³

2018

European Urology Supplements

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis

Tao¹,

Shen²,

Xiao³

2018

European Urology Supplements

View full text Add to dashboard Cite

“…KEYNOTE-028, a multicohort phase Ib study of pembrolizumab (Merck), another anti-PD-1 monoclonal antibody, in patients with advanced solid tumors, enrolled 23 patients with mCRPC. Of these, 3 (13%) had a confirmed partial response (PR) and 9 (39%) had stable disease (15). The lack of responses in both studies were possibly due to the fact that responses may correlate with PD-L1 expression, which is minimal in prostate cancer (16).…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy of Prostate Cancer: Facts and Hopes

Bilušić

Madan

Gulley

2017

Clinical Cancer Research

201

182

View full text Add to dashboard Cite

In the last few years immunotherapy has become an important cancer treatment modality and while the principles of immunotherapy evolved over many decades, the FDA approvals of sipuleucel-T and ipilimumab began a new wave in immuno-oncology. Despite the current enthusiasm, it is unlikely that any of the immunotherapeutics alone can dramatically change prostate cancer outcomes, but combination strategies are more promising and provide a reason for optimism. Several completed and ongoing studies have shown that the combination of cancer vaccines or checkpoint inhibitors with different immunotherapeutic agents, hormonal therapy (enzalutamide), radiation therapy (radium 223), DNA-damaging agents (olaparib), or chemotherapy (docetaxel) can enhance immune responses and induce more dramatic, long-lasting clinical responses without significant toxicity. The goal of prostate cancer immunotherapy does not have to be complete eradication of advanced disease, but rather the return to an immunologic equilibrium with an indolent disease state. In addition to determining the optimal combination of treatment regimens, efforts are also ongoing to discover biomarkers of immune response. With such concerted efforts, the future of immunotherapy in prostate cancer looks brighter than ever.

show abstract

“…Prostate cancer (PCa) remains among the most relevant tumors in men [1]. While age, ethnicity, and family history maintain their etiologic role as risk factors, throughout the last decades, viral and bacterial infections, inflammatory stimuli, and environmental factors, such as diet and lifestyle, have gained attention for their recognized involvement in terms of prostate biology [2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%